BSc. (Eng.), MSc.(WCU), (Micro/Stats UNISA), D.Pharm
(Wits)., PHD (Neuro IAGIM. U.)
/ - 2015/6. - Total Parts: 20 - Pages 110 and growing)
MORE ADVANCED MS Article - www.LocumUSA.com ; Ref: "Article
of the Month"
J. D. Block - Neuro-Immuno-Epidemiologist (N.I.E.)
J. D. Block served for the duration of the development of COP 1 as
a senior medical/pharmaceutical researcher and part of the Teva COP
1 innovative research team in the early nineties that rapidly developed
Teva's first MS immuno-modulating drug Glatiramer Acetate (CopaxoneTM).
As Chief Scientist as well as Teva's Group Scientific Research Auditor,
and by touching each and every part of the Teva's organization and
the overall scientific team, Teva rapidly attained New Drug Registration
with the FDA under J. D. Block scientific and technical guidance and
regulatory department training, GRP, GMP GLP, SOPs, Analytical audits
and global organization overview (from early active material synthesis
to manufacture and then final freeze dried packaging).
MORE ADVANCED MS Article - www.LocumUSA.com ; Ref:
of the Month"
J. D. Block - Neuro-Immuno-Epidemiologist
ISRAEL Israeli Jews have a prevalence of up to 62 per 100,000, but
Christians (35 per 100,000), Moslem Arabs (15), Druze (11), and Bedouins
(17) have lower rates (Alter et al 2006). Genetically similar immigrants
have half the rate of native-born Jews, suggesting an environmental
factor. Other groups also have a significantly lower incidence of
multiple sclerosis (Caucasians Hispanics Latino's black African Americans,
Asians African Natives, Inuits, SWA bushman, and Romani Gypsies (almost